Full reference for HGH Fragment 176-191 — mechanism, clinical evidence, dosage protocol, safety profile, and current COA-verified vendor pricing.
Research context only. AOD-9604 is not FDA-approved. All content is educational. Not medical advice.
AOD-9604 (HGH Fragment 176-191) is a synthetic peptide comprising the C-terminal fragment of human growth hormone, developed by Monash University's Professor Frank Ng. It was isolated after researchers identified that the lipolytic (fat-burning) activity of HGH resided in a specific region of the molecule, separate from its growth-promoting effects mediated through IGF-1.
AOD-9604 stimulates lipolysis and inhibits lipogenesis through mechanisms that mirror endogenous HGH's fat-metabolism activity, while bypassing the growth hormone receptor pathway responsible for IGF-1 production and anabolic effects.
The compound activates beta-3 adrenergic receptors in adipose tissue, triggering the release of stored fatty acids. It also appears to modulate adiponectin and other adipokines in ways that favor fat oxidation. Critically, it does not trigger downstream IGF-1 signaling — confirmed in clinical trials where IGF-1 levels were unchanged from baseline at all doses tested.
Clinical confirmation of selectivity: Multiple Phase 1 and 2 trials measured IGF-1, insulin, glucose, and other metabolic markers. None showed statistically significant changes from baseline, confirming the compound's selective mechanism in humans, not just animal models.
Multiple rodent studies demonstrated significant dose-dependent reductions in body fat with AOD-9604 administration, with no effect on linear growth, IGF-1 levels, or glucose tolerance. These results established the selectivity profile that made Phase 1 trials justifiable.
Initial human safety trials established tolerability and confirmed that the compound did not raise IGF-1 or affect glucose metabolism in healthy volunteers. The safety profile was sufficiently clean to proceed to Phase 2.
Phase 2 randomized controlled trials in obese subjects demonstrated statistically significant reductions in body fat mass compared to placebo over 12 weeks at a 500mcg daily dose. Lean mass was preserved. Metabolic markers including HbA1c, fasting glucose, and lipid panels showed no adverse changes.
| Parameter | AOD-9604 (500mcg/day) | Placebo |
|---|---|---|
| Fat mass change | Significant reduction | Minimal change |
| Lean mass | Preserved | Preserved |
| IGF-1 | No change from baseline | No change |
| Fasting glucose | No significant change | No change |
| Adverse events | No serious AEs | No serious AEs |
| Parameter | Value | Notes |
|---|---|---|
| Standard dose | 300–500 mcg/day | Clinical trials used 500mcg; some protocols use 250–300mcg |
| Timing | Fasted AM | Inject before eating; low insulin enhances lipolytic response |
| Frequency | Once daily | Short half-life (~30 min) makes daily dosing standard |
| Cycle length | 12–16 weeks | Most research protocols; clinical trials used 12 weeks |
| Administration | SubQ injection | Abdomen or thigh; rotate sites |
| Reconstitution | 1–2 mL BAC water per vial | Standard peptide reconstitution; refrigerate after mixing |
Stack context: AOD-9604 is often researched alongside GLP-1 peptides (retatrutide, semaglutide) for combined appetite suppression + direct lipolysis, and alongside tesamorelin for dual-pathway fat targeting. Its clean safety profile makes combination protocols relatively straightforward from a mechanistic standpoint.
| Side Effect | Frequency | Notes |
|---|---|---|
| Injection site reactions | Occasional | Mild redness/swelling; resolves quickly |
| Headache | Occasional | Mild; reported in some trial participants |
| Flushing | Occasional | Transient; resolves within minutes of injection |
| IGF-1 elevation | Not observed | Confirmed absent in all clinical trials |
| Glucose dysregulation | Not observed | No significant change from baseline in trials |
| Fluid retention | Not observed | Absent — unlike full HGH |
| Joint pain | Not observed | Not a reported adverse event in trials |
COA-verified vendor pricing with promo codes, reconstitution guide, and dosing protocol.
View Pricing → Dosage Calculator